2013, Número 3
<< Anterior Siguiente >>
An Med Asoc Med Hosp ABC 2013; 58 (3)
Sarcoma del estroma endometrial con elementos tipo cordones sexuales del ovario. «Una rara variante histológica»
Martínez-Consuegra N, Ibarrola BAE
Idioma: Español
Referencias bibliográficas: 30
Paginas: 201-207
Archivo PDF: 530.88 Kb.
RESUMEN
Los tumores del estroma endometrial son raros y representan entre el 2 y 6% de la totalidad de tumores uterinos. Dentro de los tumores que conforman este grupo, el sarcoma del estroma endometrial de bajo grado (SEEBG) es el más frecuente. En 1976, Clement y Scully describieron dos variantes de tumores uterinos con elementos similares a los cordones sexuales, una de ellas en sarcomas del estroma endometrial (TEEETCS). Se ha reportado la asociación del tratamiento previo con Tamoxifén, el estímulo estrogénico prolongado e historia de radioterapia pélvica. A continuación, presentamos el caso de una rara variante histológica de sarcoma del estroma endometrial de bajo grado con elementos de tipo cordones sexuales, en una mujer previamente tratada con bloqueadores de la aromatasa (Anastrozol) y radioterapia por carcinoma mamario. Caso informado por primera vez en la literatura.
REFERENCIAS (EN ESTE ARTÍCULO)
Baker P, Oliva E. Endometrial stromal tumours of the uterus: a practical approach using conventional morphology and ancillary techniques. J Clin Pathol. 2007; 60 (3): 235-43.
Berceanu S, Pătraşcu A, Berceanu C, Tica AA, Bădulescu A. Endometrial stromal sarcoma: clinico-pathological report of four cases and review of the literature. Rom J Morphol Embryol. 2008; 49 (2): 251-5.
Czernobilsky B. Uterine tumors resembling ovarian sex cord tumors: an update. Int J Gynecol Pathol. 2008; 27 (2): 229-35.
Pang LC. Endometrial stromal sarcoma with sex cord-like differentiation associated with tamoxifen therapy. South Med J. 1998; 91 (6): 592-4.
Mark RJ, Poen J, Tran LM, Fu YS, Heaps J, Parker RG. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol. 1996; 19 (1): 59-64.
D’Angelo E, Prat J. Uterine sarcomas: a review. Gynecol Oncol. 2010; 116 (1): 131-9.
Chew I, Oliva E. Endometrial Stromal Sarcomas. A review of potential prognostic factors. Ad Anat Pathol. 2010; 17 (2): 113-20.
Saga Y, Ohwada M, Kohno T, Takayashiki N, Suzuki M. High-grade endometrial stromal sarcoma after treatment with tamoxifen in a patient treated for breast cancer. Int J Gynecol Cancer. 2003; 13 (5): 690-2.
Norris HJ, Taylor HB. Mesenchymal tumors of the uterus: A clinical and pathological study of 53 endometrial stromal tumors. Cancer. 1966; 19: 755-66.
Clement PB, Scully RE. Uterine tumors resembling ovarian sex cord tumors. A clinicopathologic analysis of fourteen cases. Am J Clin Pathol. 1976; 66: 512-25.
Zernobilsky B. Uterine tumors resembling ovarian sex cord tumors: an update. Int J Gynecol Pathol. 2008; 27 (2): 229-35.
Irving JA, Carinelli S, Prat J. Uterine tumors resembling ovarian sex cord tumors are polyphenotipic neoplasms with true sex cord differentiation. Mod Pathol. 2006; 19: 17-24.
Bodner K, Bodner-Adler B, Obermair A, Windbichler G, Petru E, Mayerhofer S et al. Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol. 2001; 81 (2): 160-5.
Fukunaga M, Miyazawa Y, Ushigome S. Endometrial low-grade stromal sarcoma with ovarian sex cord-like differentiation: report of two cases with an immunohistochemical and flow cytometric study. Pathol Int. 1997; 47 (6): 412-5.
Mccluggage WG, Shah V, Walsh MY, Toner PG. Uterine tumour resembling ovarian sex cord tumour: Evidence for smooth muscle differentiation. Histopathology. 1993; 23: 83-85.
Dong Y, Shi XJ, Li T, Zhang Y. The morphologic features of endometrial stromal sarcoma and its metastases. Zhonghua Bing Li Xue Za Zhi. 2005; 34 (3): 163-6.
Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: A report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol. 2002; 26 (9): 1142-50.
Beer TW, Buchanan R, Buckley CH. Uterine stromal sarcoma following tamoxifen treatment. J Clin Pathol. 1995; 48 (6): 596.
Gal D, Weiselberg L, Runowicz CD. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.J Natl Cancer Inst. 1994; 86 (16): 1252-3 [author reply 1255].
Pang LC. Endometrial stromal sarcoma with sex cord-like differentiation associated with tamoxifen therapy. South Med J. 1998; 91 (6): 592-4.
Salamanca G F. Tamoxifén y carcinogénesis en el endo- metrio. Gac Med Mex. 2006; 142 (2): 171-172.
Miliaras D, Bontis J. Uterine tumor resembling sex-cord ovarian tumors: one more case of the pure type suggests a neoplasm with benign behavior. Eur J Gynaecol Oncol. 1997; 18 (2): 133-5.
Engin H. High-grade endometrial stromal sarcoma following tamoxifen treatment. Eur J Gynaecol Oncol. 2005; 26 (3): 288-90.
Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol. 2003; 86 (3-5): 225-30.
Lönning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of anastrozole. Breast Cancer Res Treat. 1998; 49 (Suppl 1): S53-7; discussion S73-7.
Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat. 1994; 30 (1): 103-11.
Tsukagoshi S. Development of a novel aromatase inhibitor, anastrozole (Arimidex): Its basic and clinical studies. Gan To Kagaku Ryoho. 2001; 28 (4): 549-60.
Pérez E. Safety of aromatase inhibitors in the adjuvant setting. Breast Cancer Res Treat. 2007; 105 (Suppl 1): 75-89. Epub 2007 Oct 3.
Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002; 52 (5): 1231-7.
Mark RJ, Poen J, Tran LM, Fu YS, Heaps J, Parker RG. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol. 1996; 19 (1): 59-64.